STERICALLY STABILIZED AMPHOTERICIN B-LIPOSOMES - TOXICITY AND BIODISTRIBUTION IN MICE

被引:26
作者
VANETTEN, EWM [1 ]
VANVIANEN, W [1 ]
TIJHUIS, RHG [1 ]
STORM, G [1 ]
BAKKERWOUDENBERG, IAJM [1 ]
机构
[1] UNIV UTRECHT,DEPT PHARMACEUT,UTRECHT,NETHERLANDS
关键词
AMPHOTERICIN B; BIODISTRIBUTION; TOXICITY; LIPOSOME; POLY(ETHYLENE GLYCOL);
D O I
10.1016/0168-3659(95)00071-F
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In this study it was investigated whether long-circulating amphotericin B (AMB) containing liposomes could be prepared by incorporation of polyethylene glycol (1900) derivatized distearoylphosphatidylethanolamine (PEG-DSPE), and whether the incorporation of PEG-DSPE affected toxicity and biodistribution of the preparation in mice. Toxicity of two formulations of liposomes containing both PEG-DSPE and AMB (PEG-AMB-LIP, types 1 and 2) was compared with that of AMB-liposomes without PEG-DSPE (AMB-LIP) as well as that of MB-deoxycholate (AMB-DOC). The maximum tolerated dosage (MTD) of AMB-DOC, expressed in terms of death during treatment for 5 consecutive days or significant increases in the parameters used to monitor renal and hepatic functions, was 0.8 mg/kg per day. AMB-LIP were the least toxic, the MTD being 11 mg/kg per day. The formulation with AMB complexed to DSPG (PEG-AMB-LIP type 1) was as toxic as AMB-DOC. This PEG-AMB-LIP formulation was omitted from further studies on biodistribution. With AMB complexed to PEG-DSPE (PEG-AMB-LIP type 2) toxicity was substantially reduced, resulting in a MTD of 9 mg/kg per day. Biodistribution of radiolabeled PEG-AMB-LIP type 2 was compared with that of AMB-LIP. Blood residence time of PEG-AMB-LIP type 2 was prolonged as compared to AMB-LTP; For PEG-AMB-LIP type 2 at 24 h after administration 30% of the injected dosage of AMB in intact liposomes was circulating versus 6% for AMB-LIP.
引用
收藏
页码:123 / 129
页数:7
相关论文
共 24 条
[11]   AMPHOTERICIN-B AND ITS DELIVERY BY LIPOSOMAL AND LIPID FORMULATIONS [J].
GATES, C ;
PINNEY, RJ .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1993, 18 (03) :147-153
[12]   INDIUM-III - NEW RADIONUCLIDE LABEL FOR STUDYING HUMAN-PLATELET KINETICS [J].
HEATON, WA ;
DAVIS, HH ;
WELCH, MJ ;
MATHIAS, CJ ;
JOIST, JH ;
SHERMAN, LA ;
SIEGEL, BA .
BRITISH JOURNAL OF HAEMATOLOGY, 1979, 42 (04) :613-622
[13]   LIPOSOMAL AND LIPID FORMULATIONS OF AMPHOTERICIN-B - CLINICAL PHARMACOKINETICS [J].
JANKNEGT, R ;
DEMARIE, S ;
BAKKERWOUDENBERG, IAJM ;
CROMMELIN, DJA .
CLINICAL PHARMACOKINETICS, 1992, 23 (04) :279-291
[14]   AMPHIPATHIC POLYETHYLENEGLYCOLS EFFECTIVELY PROLONG THE CIRCULATION TIME OF LIPOSOMES [J].
KLIBANOV, AL ;
MARUYAMA, K ;
TORCHILIN, VP ;
HUANG, L .
FEBS LETTERS, 1990, 268 (01) :235-237
[15]  
KLIBANOV AL, 1992, J LIPOSOME RES, V2, P321
[16]   STERICALLY STABILIZED LIPOSOMES - A HYPOTHESIS ON THE MOLECULAR-ORIGIN OF THE EXTENDED CIRCULATION TIMES [J].
LASIC, DD ;
MARTIN, FJ ;
GABIZON, A ;
HUANG, SK ;
PAPAHADJOPOULOS, D .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1070 (01) :187-192
[17]   SYSTEMICALLY ADMINISTERED ANTIFUNGAL AGENTS - A REVIEW OF THEIR CLINICAL-PHARMACOLOGY AND THERAPEUTIC APPLICATIONS [J].
LYMAN, CA ;
WALSH, TJ .
DRUGS, 1992, 44 (01) :9-35
[18]   STERICALLY STABILIZED LIPOSOMES - IMPROVEMENTS IN PHARMACOKINETICS AND ANTITUMOR THERAPEUTIC EFFICACY [J].
PAPAHADJOPOULOS, D ;
ALLEN, TM ;
GABIZON, A ;
MAYHEW, E ;
MATTHAY, K ;
HUANG, SK ;
LEE, KD ;
WOODLE, MC ;
LASIC, DD ;
REDEMANN, C ;
MARTIN, FJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (24) :11460-11464
[19]  
PATTERSON TF, 1989, EUR J CANCER CLIN ON, V25, pS63
[20]   INFLUENCE OF SURFACE HYDROPHILICITY OF LIPOSOMES ON THEIR INTERACTION WITH PLASMA-PROTEIN AND CLEARANCE FROM THE CIRCULATION - STUDIES WITH POLY(ETHYLENE GLYCOL)-COATED VESICLES [J].
SENIOR, J ;
DELGADO, C ;
FISHER, D ;
TILCOCK, C ;
GREGORIADIS, G .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1062 (01) :77-82